Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and Gefitinib First-line Treatment in EGFR-mutant Advanced Non-squamous NSCLC
ChiCTR-IPR-17010776Phase 4Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Apr 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial in Non-small cell lung cancer (NS-NSCLC) comparing Gefitinib + Apatinib with Gefitinib monotherapy (2 arms). Primary endpoint: progression-free survival. Planned start Apr 2017; status: not yet recruiting.
02
Drugs
Rivoceranibgefitinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR-IPR-17010776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010776.